Equities

Roquefort Therapeutics PLC

ROQ:LSE

Roquefort Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.25
  • Today's Change0.00 / 0.00%
  • Shares traded4.73k
  • 1 Year change-23.64%
  • Beta--
Data delayed at least 20 minutes, as of May 30 2024 12:19 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Company’s portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.

  • Revenue in GBP (TTM)--
  • Net income in GBP--
  • Incorporated2020
  • Employees--
  • Location
    Roquefort Therapeutics PLC85 Great Portland Street,, First FloorLONDON W1W 7LTUnited KingdomGBR
  • Phone+44 203 918 8633
  • Websitehttps://www.roquefortplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mineral & Financial Investments Ltd2.28m1.44m4.43m31.003.220.442--1.940.03730.03730.05930.27150.2416--217.52--15.1919.8415.5220.28----62.8774.20----0.001--84.58--72.41------
British & American Investment Trust Plc-1.19m-2.32m4.63m8.00---------0.1044-0.1044-0.04230.1805-0.0924-------15.273.34-19.964.51--94.34--40.87----0.2149---170.92---470.13------
Oneiro Energy PLC0.00-276.49k4.67m----5.98-----0.0099-0.00990.000.01760.00-------64.49---71.38--------------0.00-------10.00------
Vox Valor Capital Ltd4.37m-146.88k4.75m----0.6701--1.09-0.00006-0.000060.00180.0030.417--2.75---1.40-17.80-1.66-21.78-----3.36-20.06---0.20640.2287---59.70--94.04------
Bay Capital PLC0.00-1.31m4.90m3.00--0.9576-----0.0187-0.01870.000.07310.00----0.00-20.84---22.67--------------0.00-------419.93------
Sure Ventures PLC-208.43k-638.49k5.11m0.00--0.6435-----0.0949-0.0949-0.03111.13-0.0254-------7.776.29-7.906.41--74.37--48.28----0.0264---100.01---119.56------
APQ Global Ltd6.31m-5.37m5.12m----1.18--0.8117-0.0683-0.06830.08030.05540.1812--25.17---15.40-19.15-15.60-19.3098.8599.14-85.02-206.81--0.38330.8664--4.37-6.66-115.53---16.85--
Wildcat Petroleum PLC0.0015.00k5.47m2.00--14.54----0.000.000.000.00010.00----0.004.39--4.99--------------0.00------14.31------
Africa Opportunity Fund Limited0.00-1.33m5.86m0.00--0.7547-----0.1473-0.14730.000.86130.00-------11.512.53-11.632.55------31.69---0.30640.00------29.90------
Oxford Technology 2 Ventr Cptl Trst PLC-1.62m-1.81m6.05m0.00--0.4151-----0.065-0.065-0.05810.265-0.1927-------21.56-15.24-21.93-15.38------------0.00---469.84---592.39------
Roquefort Therapeutics PLC-100.00bn-100.00bn6.33m--------------------------------------------------------------
Investment Company PLC (THE)413.97k104.58k6.52m0.0044.110.986162.3615.750.08050.08050.11793.600.0349--3.54--0.88131.260.88831.28--90.5525.2630.87----0.00--705.722.24397.314.79----
Guinness VCT PLC-100.00bn-100.00bn6.53m0.00--0.954----------0.9591----------------------------0.00--------------
Bowen Fintech PLC0.00-184.79k6.60m----4.04-----0.0034-0.00340.000.02970.00-------10.11---10.77--------------0.00-------281.93------
Reabold Resources PLC0.00-7.19m7.14m4.00--0.1705-----0.0008-0.00080.000.00410.00----0.00-15.93-8.07-16.10-8.19--4.14---398.88---0.72550.00---100.00---15,886.67---27.17--
Worsley Investors Ltd685.00k892.00k8.50m2.50k9.530.5917--12.410.02640.02640.02030.42590.0479--37.03--6.23--6.37--45.84--130.22------0.00--3.64--304.16------
Data as of May 30 2024. Currency figures normalised to Roquefort Therapeutics PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.